Go Pro
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel Free GRI Stock Alerts

GRI Bio (GRI) Competitors

GRI Bio logo
$1.51 +0.04 (+2.72%)
Closing price 07/21/2026 04:00 PM Eastern
Extended Trading
$1.50 -0.01 (-0.33%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

GRI vs. MYNZ, GDTC, KPRX, BCLI, and PHXM

Should you buy GRI Bio stock or one of its competitors? MarketBeat compares GRI Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with GRI Bio include Mainz Biomed (MYNZ), CytoMed Therapeutics (GDTC), Kiora Pharmaceuticals (KPRX), Brainstorm Cell Therapeutics (BCLI), and PHAXIAM Therapeutics (PHXM). These companies are all part of the "pharmaceutical products" industry.

How does GRI Bio compare to Mainz Biomed?

GRI Bio (NASDAQ:GRI) and Mainz Biomed (NASDAQ:MYNZ) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership, media sentiment and earnings.

GRI Bio has a beta of -1.21, suggesting that its stock price is 221% less volatile than the broader market. Comparatively, Mainz Biomed has a beta of 0.31, suggesting that its stock price is 69% less volatile than the broader market.

GRI Bio currently has a consensus target price of $32.00, indicating a potential upside of 2,019.21%. Given GRI Bio's stronger consensus rating and higher possible upside, analysts clearly believe GRI Bio is more favorable than Mainz Biomed.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GRI Bio
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Mainz Biomed
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50

Mainz Biomed's return on equity of 0.00% beat GRI Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
GRI BioN/A -199.52% -143.23%
Mainz Biomed N/A N/A N/A

GRI Bio has higher earnings, but lower revenue than Mainz Biomed. GRI Bio is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GRI BioN/AN/A-$11.96M-$74.16N/A
Mainz Biomed$659.94K15.93-$21.65M-$65.60N/A

34.0% of GRI Bio shares are held by institutional investors. 8.7% of GRI Bio shares are held by insiders. Comparatively, 18.2% of Mainz Biomed shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Mainz Biomed had 1 more articles in the media than GRI Bio. MarketBeat recorded 1 mentions for Mainz Biomed and 0 mentions for GRI Bio. Mainz Biomed's average media sentiment score of 0.75 beat GRI Bio's score of 0.40 indicating that Mainz Biomed is being referred to more favorably in the news media.

Company Overall Sentiment
GRI Bio Neutral
Mainz Biomed Positive

Summary

Mainz Biomed beats GRI Bio on 9 of the 14 factors compared between the two stocks.

How does GRI Bio compare to CytoMed Therapeutics?

CytoMed Therapeutics (NASDAQ:GDTC) and GRI Bio (NASDAQ:GRI) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation.

CytoMed Therapeutics has higher revenue and earnings than GRI Bio.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CytoMed Therapeutics$250K45.43-$3.10MN/AN/A
GRI BioN/AN/A-$11.96M-$74.16N/A

GRI Bio has a consensus target price of $32.00, indicating a potential upside of 2,019.21%. Given GRI Bio's stronger consensus rating and higher probable upside, analysts clearly believe GRI Bio is more favorable than CytoMed Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CytoMed Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
GRI Bio
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, GRI Bio's average media sentiment score of 0.40 beat CytoMed Therapeutics' score of 0.00 indicating that GRI Bio is being referred to more favorably in the news media.

Company Overall Sentiment
CytoMed Therapeutics Neutral
GRI Bio Neutral

CytoMed Therapeutics has a beta of 0.01, indicating that its stock price is 99% less volatile than the broader market. Comparatively, GRI Bio has a beta of -1.21, indicating that its stock price is 221% less volatile than the broader market.

CytoMed Therapeutics' return on equity of 0.00% beat GRI Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
CytoMed TherapeuticsN/A N/A N/A
GRI Bio N/A -199.52%-143.23%

0.0% of CytoMed Therapeutics shares are owned by institutional investors. Comparatively, 34.0% of GRI Bio shares are owned by institutional investors. 8.7% of GRI Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

GRI Bio beats CytoMed Therapeutics on 6 of the 11 factors compared between the two stocks.

How does GRI Bio compare to Kiora Pharmaceuticals?

Kiora Pharmaceuticals (NASDAQ:KPRX) and GRI Bio (NASDAQ:GRI) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, analyst recommendations, media sentiment, earnings, dividends and profitability.

77.0% of Kiora Pharmaceuticals shares are held by institutional investors. Comparatively, 34.0% of GRI Bio shares are held by institutional investors. 0.5% of Kiora Pharmaceuticals shares are held by insiders. Comparatively, 8.7% of GRI Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, GRI Bio's average media sentiment score of 0.40 beat Kiora Pharmaceuticals' score of 0.00 indicating that GRI Bio is being referred to more favorably in the news media.

Company Overall Sentiment
Kiora Pharmaceuticals Neutral
GRI Bio Neutral

Kiora Pharmaceuticals presently has a consensus target price of $10.00, suggesting a potential upside of 295.26%. GRI Bio has a consensus target price of $32.00, suggesting a potential upside of 2,019.21%. Given GRI Bio's higher probable upside, analysts clearly believe GRI Bio is more favorable than Kiora Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kiora Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
GRI Bio
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Kiora Pharmaceuticals has a beta of -0.4, indicating that its share price is 140% less volatile than the broader market. Comparatively, GRI Bio has a beta of -1.21, indicating that its share price is 221% less volatile than the broader market.

Kiora Pharmaceuticals has higher revenue and earnings than GRI Bio. Kiora Pharmaceuticals is trading at a lower price-to-earnings ratio than GRI Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kiora Pharmaceuticals$16.02M0.70-$10.84M-$2.71N/A
GRI BioN/AN/A-$11.96M-$74.16N/A

Kiora Pharmaceuticals' return on equity of -59.30% beat GRI Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Kiora PharmaceuticalsN/A -59.30% -41.23%
GRI Bio N/A -199.52%-143.23%

Summary

Kiora Pharmaceuticals beats GRI Bio on 7 of the 11 factors compared between the two stocks.

How does GRI Bio compare to Brainstorm Cell Therapeutics?

GRI Bio (NASDAQ:GRI) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, risk, institutional ownership, valuation and profitability.

Brainstorm Cell Therapeutics' return on equity of 0.00% beat GRI Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
GRI BioN/A -199.52% -143.23%
Brainstorm Cell Therapeutics N/A N/A -519.50%

GRI Bio presently has a consensus price target of $32.00, indicating a potential upside of 2,019.21%. Given GRI Bio's higher possible upside, equities research analysts clearly believe GRI Bio is more favorable than Brainstorm Cell Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GRI Bio
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Brainstorm Cell Therapeutics
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, Brainstorm Cell Therapeutics had 1 more articles in the media than GRI Bio. MarketBeat recorded 1 mentions for Brainstorm Cell Therapeutics and 0 mentions for GRI Bio. Brainstorm Cell Therapeutics' average media sentiment score of 0.67 beat GRI Bio's score of 0.40 indicating that Brainstorm Cell Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
GRI Bio Neutral
Brainstorm Cell Therapeutics Positive

Brainstorm Cell Therapeutics is trading at a lower price-to-earnings ratio than GRI Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GRI BioN/AN/A-$11.96M-$74.16N/A
Brainstorm Cell TherapeuticsN/AN/A-$11.62M-$1.64N/A

34.0% of GRI Bio shares are held by institutional investors. Comparatively, 14.3% of Brainstorm Cell Therapeutics shares are held by institutional investors. 8.7% of GRI Bio shares are held by insiders. Comparatively, 11.2% of Brainstorm Cell Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

GRI Bio has a beta of -1.21, meaning that its share price is 221% less volatile than the broader market. Comparatively, Brainstorm Cell Therapeutics has a beta of 0.23, meaning that its share price is 77% less volatile than the broader market.

Summary

Brainstorm Cell Therapeutics beats GRI Bio on 7 of the 12 factors compared between the two stocks.

How does GRI Bio compare to PHAXIAM Therapeutics?

GRI Bio (NASDAQ:GRI) and PHAXIAM Therapeutics (NASDAQ:PHXM) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, dividends, media sentiment and valuation.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GRI BioN/AN/A-$11.96M-$74.16N/A
PHAXIAM TherapeuticsN/AN/A-$240KN/AN/A

GRI Bio has a beta of -1.21, indicating that its stock price is 221% less volatile than the broader market. Comparatively, PHAXIAM Therapeutics has a beta of 2.35, indicating that its stock price is 135% more volatile than the broader market.

34.0% of GRI Bio shares are owned by institutional investors. Comparatively, 0.4% of PHAXIAM Therapeutics shares are owned by institutional investors. 8.7% of GRI Bio shares are owned by company insiders. Comparatively, 1.9% of PHAXIAM Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, GRI Bio's average media sentiment score of 0.40 beat PHAXIAM Therapeutics' score of 0.00 indicating that GRI Bio is being referred to more favorably in the media.

Company Overall Sentiment
GRI Bio Neutral
PHAXIAM Therapeutics Neutral

GRI Bio currently has a consensus target price of $32.00, indicating a potential upside of 2,019.21%. Given GRI Bio's stronger consensus rating and higher probable upside, equities research analysts clearly believe GRI Bio is more favorable than PHAXIAM Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GRI Bio
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
PHAXIAM Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

PHAXIAM Therapeutics' return on equity of 0.00% beat GRI Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
GRI BioN/A -199.52% -143.23%
PHAXIAM Therapeutics N/A N/A N/A

Summary

GRI Bio beats PHAXIAM Therapeutics on 6 of the 10 factors compared between the two stocks.

Get GRI Bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for GRI and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GRI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GRI vs. The Competition

Export
MetricGRI BioMED IndustryMedical SectorNASDAQ Exchange
Market Cap$2.60M$3.63B$6.80B$12.31B
Dividend YieldN/A2.18%2.67%9.67%
P/E Ratio-0.0220.6226.9324.18
Price / SalesN/A175.04488.6079.77
Price / CashN/A150.2449.7159.37
Price / Book0.368.1710.676.25
Net Income-$11.96M$23.81M$3.60B$331.66M
7 Day Performance-6.79%-1.67%-1.01%-1.32%
1 Month Performance-19.25%1.06%1.58%-1.74%
1 Year Performance-97.36%43.82%24.13%18.04%

GRI Bio Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GRI
GRI Bio
3.2561 of 5 stars		$1.51
+2.7%		$32.00
+2,019.2%		-97.3%$2.60MN/AN/A1
MYNZ
Mainz Biomed
0.5142 of 5 stars		$1.26
-7.4%		N/A-45.5%$11.42M$659.94KN/A30
GDTC
CytoMed Therapeutics
0.9822 of 5 stars		$0.99
+3.5%		N/A-52.9%$11.36M$250KN/AN/A
KPRX
Kiora Pharmaceuticals
2.3292 of 5 stars		$2.48
+0.8%		$10.00
+303.2%		-18.1%$10.90M$16.02MN/A10
BCLI
Brainstorm Cell Therapeutics
0.6574 of 5 stars		$0.96
-8.2%		N/A+22.7%$10.59MN/AN/A40

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:GRI) was last updated on 7/22/2026 by MarketBeat.com Staff.
From Our Partners
BlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
The options guide that actually starts at the beginning
Most options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...
Base Camp Trading | Sponsoredtc pixel
Elon says “don’t save money.” Is he right?
Robert Kiyosaki, author of Rich Dad Poor Dad, says you don't have to wait for Elon Musk's vision of universal ...
Freedom Financial | Sponsoredtc pixel
The Starlink of Energy
A portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...
Monument Traders Alliance | Sponsoredtc pixel
30-Year market veteran reveals America’s #1 Stock
Market veteran Jim Woods has flagged triple-digit gains multiple times in under two months - 151% on Netflix, ...
Eagle Publishing | Sponsoredtc pixel
Forget SpaceX… this is the REAL #1 IPO of 2026
While SpaceX and OpenAI dominate IPO headlines, one private company is reportedly seeing the fastest revenue g...
The Oxford Club | Sponsoredtc pixel
Man who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”
In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...
Paradigm Press | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel